9HODE stimulates cell proliferation and extracellular matrix synthesis in human mesangial cells via PPARγ

Experimental Biology and Medicine

Volumn 229, Issue 10, 2004, Pages 1053-1060

  Negishi, Mayumi ^a   Shimizu, Hiroyuki ^a   Okada, Shuichi ^a   Kuwabara, Atsushi ^b   Okajima, Fumikazu ^c   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GUNMA UNIVERSITY HOSPITAL   (Japan)

^c GUNMA UNIVERSITY   (Japan)

Author keywords

9HODE; Mesangial cell; Oxidized LDL; PPAR

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTISENSE OLIGONUCLEOTIDE; BROXURIDINE; COLLAGEN TYPE 4; CORIOLIC ACID; DIMORPHECOLIC ACID; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ARTICLE; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; EXAMINATION; EXPOSURE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; LIPOPROTEIN BLOOD LEVEL; MESANGIUM CELL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; WESTERN BLOTTING;

EID: 7244224711     PISSN: 15353702     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020422901010     Document Type: Article

References (45)

1. Steffes MW, Osterby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 38:1077-1081, 1989.
2. Striker LJ, Doi T, Elliot S, Striker GE. The contribution of glomerular mesangial cells to progressive glomerulosclerosis. Semin Nephrol 9:318-328, 1989.
3. Eng E, Floege J, Young BA, Couser WG, Johnson RJ. Does extracellular matrix expansion in glomerular disease require mesangial cell proliferation? Kidney Int Suppl 45:S45-S47, 1994.
4. Akiba S, Chiba M, Mukaida Y, Sato T. Involvement of reactive oxygen species and SP-1 in fibronectin production by oxidized LDL. Biochem Biophys Res Commun 310:491-497, 2003.
5. Van Tits L, De Graaf J, Hak-Lemmers H, Bredie S, Demacker P, Holvoet P, Stalenhoef A. Increased levels of low-density lipoprotein oxidation in patients with familial hypercholesterolemia and in endstage renal disease patients on hemodialysis. Lab Invest 83:13-21, 2003.
6. Lee HS, Kim BC, Hong HK, Kim YS. LDL stimulates collagen mRNA synthesis in mesangial cells through induction of PKC and TGF-beta expression. Am J Physiol 277:F369-F376, 1999.
7. Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, Shimamura K, Kimura J, Michishita I, Suzuki T, Nagai R. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 20:2243-2247, 2000.
8. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collen D, Muls E, Van de Werf F. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21:844-848, 2001.
9. Ujihara N, Sakka Y, Takeda M, Hirayama M, Ishii A, Tomonaga O, Babazono T, Takahashi C, Yamashita K, Iwamoto Y. Association between plasma oxidized low-density lipoprotein and diabetic nephropathy. Diabetes Res Clin Pract 58:109-114, 2002.
10. Ozaki M, Yamada Y, Matoba K, Otani H, Mune M, Yukawa S, Sakamoto W. Phospholipase A2 activity in ox-LDL-stimulated mesangial cells and modulation by alpha-tocopherol. Kidney Int Suppl 71:5171-5173, 1999.
11. Wheeler DC, Chana RS, Topley N, Petersen MM, Davies M, Williams JD. Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury. Kidney Int 45:1628-1636, 1994.
12. Kamanna VS, Pai R, Ha H, Kirschenbaum MA, Roh DD. Oxidized low-density lipoprotein stimulates monocyte adhesion to glomerular endothelial cells. Kidney Int 55:2192-2202, 1999.
13. Chana RS, Wheeler DC. Fibronectin augments monocyte adhesion to low-density lipoprotein-stimulated mesangial cells. Kidney Int 55:179-188, 1999.
14. Kamanna VS, Pai R, Roh DD, Kirschenbaum MA. Oxidative modification of low-density lipoprotein enhances the murine mesangial cell cytokines associated with monocyte migration, differentiation, and proliferation. Lab Invest 74:1067-1079, 1996.
15. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-gamma. Cell 93:229-240, 1998.
16. Asano T, Wakisaka M, Yoshinari M, Iino K, Sonoki K, Iwase M, Fujishima M. Peroxisome proliferator-activated receptor gamma1 (PPAR-gamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation. Biochim Biophys Acta 1497:148-154, 2000.
17. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137:354-366, 1996.
18. Guan Y, Zhang Y, Schneider A, Davis L, Breyer RM, Breyer MD. Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature. Am J Physiol Renal Physiol 281:F1036-F1046, 2001.
19. Panzer U, Schneider A, Guan Y, Reinking R, Zahner G, Harendza S, Wolf G, Thaiss F, Stahl RA. Effects of different PPAR-gamma-agonists on MCP-1 expression and monocyte recruitment in experimental glomerulonephritis. Kidney Int 62:455-464, 2002.
20. Nikitakis NG, Hebert C, Lopes MA, Reynolds MA, Sauk JJ. PPAR-gamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells. Int J Cancer 98:817-823, 2002.
21. Rzymkiewicz DM, Tetsuka T, Daphna-Iken D, Srivastava S, Morrison AR. Interleukin-1beta activates protein kinase C zeta in renal mesangial cells. Potential role in prostaglandin E2 up-regulation. J Biol Chem 271:17241-17246, 1996.
22. Creely JJ, DiMari SJ, Howe AM, Haralson MA. Effects of transforming growth factor-beta on collagen synthesis by normal rat kidney epithelial cells. Am J Pathol 140:45-55, 1992.
23. Fine LG, Ong AC, Norman JT. Mechanisms of tubulo-interstitial injury in progressive renal diseases. Eur J Clin Invest 23:259-265, 1993.
24. Goyal M, Wiggins R. Fibronectin mRNA and protein accumulation, distribution, and breakdown in rabbit anti-glomerular basement membrane disease. J Am Soc Nephrol 1:1334-1342, 1991.
25. Ihm CG, Lee GS, Nast CC, Artishevsky A, Guillermo R, Levin PS, Glassock RJ, Adler SG. Early increased renal procollagen alpha 1 (IV) mRNA levels in streptozotocin induced diabetes. Kidney Int 41:768-777, 1992.
26. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall. Z Kardiol 90:125-132, 2001.
27. Napoli C, Sugano M, Tsuchida K, Makino N. Oxidation of LDL, atherogenesis, and apoptosis: effects of soluble TNF-alpha receptor 1 on apoptosis induced by oxidized LDL in endothelial cells. Ann N Y Acad Sci 1010:698-709, 2003.
28. Sugano M, Tsuchida K, Makino N. Effects of soluble TNF-alpha receptor 1 on apoptosis induced by oxidized LDL in endothelial cells. Mol Cell Biochem 258:57-63, 2004.
29. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 91:2488-2496, 1995.
30. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M, Fogelman AM. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 85:1260-1266, 1990.
31. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 314:488-500, 1986.
32. Inoue M, Itoh H, Tanaka T, Chun TH, Doi K, Fukunaga Y, Sawada N, Yamshita J, Masatsugu K, Saito T, Sakaguchi S, Sone M, Yamahara K, Yurugi T, Nakao K. Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor-gamma. Arterioscler Thromb Vasc Biol 21:560-566, 2001.
33. Bjorkerud B, Bjorkerud S. Contrary effects of lightly and strongly oxidized LDL with potent promotion of growth versus apoptosis on arterial smooth muscle cells, macrophages, and fibroblasts. Arterioscler Thromb Vasc Biol 16:416-424, 1996.
34. Deigner HP, Claus R. Stimulation of mitogen activated protein kinase by LDL and oxLDL in human U-937 macrophage-like cells. FEBS Lett 385:149-153, 1996.
35. Kusuhara M, Chait A, Cader A, Berk BC. Oxidized LDL stimulates mitogen-activated protein kinases in smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 17:141-148, 1997.
36. Bassa BV, Roh DD, Kirschenbaum MA, Kamanna VS. Atherogenic lipoproteins stimulate mesangial cell p42 mitogen-activated protein kinase. J Am Soc Nephrol 9:488-496, 1998.
37. Ishida T, Haneda M, Maeda S, Koya D, Kikkawa R. Stretch-induced overproduction of fibronectin in mesangial cells is mediated by the activation of mitogen-activated protein kinase. Diabetes 48:595-602, 1999.
38. Schnaper HW. Cell signal transduction through the mitogen-activated protein kinase pathway. Pediatr Nephrol 12:790-795, 1998.
39. Harada-Shiba M, Kinoshita M, Kamido H, Shimokado K. Oxidized low density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms. J Biol Chem 273:9681-9687, 1998.
40. Jenkins AJ, Velarde V, Klein RL, Joyce KC, Phillips KD, Mayfield RK, Lyons TJ, Jaffa AA. Native and modified LDL activate extracellular signal-regulated kinases in mesangial cells. Diabetes 49:2160-2169, 2000.
41. Zhao M, Liu Y, Wang X, New L, Han J, Brunk UT. Activation of the p38 MAP kinase pathway is required for foam cell formation from macrophages exposed to oxidized LDL. APMIS 110:458-468, 2002.
42. Broeders N, Abramowicz D. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 61:354-355, 2002.
43. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPAR-gamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241-252, 1998.
44. Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M, Kajimoto Y, Yamasaki Y, Hori M. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 21:2135-2139, 1998.
45. Nakamura T, Ushiyama C, Suzuki S, Shimada N, Sekizuka K, Ebihara L, Koide H. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med 18:308-313, 2001.